https://jobeax.com/link/IDlPlMFSD07xEpxj Leadership in Multimodal AI and Computational Diagnostics
Act as the enterprise scientific authority for multimodal AI applied to Oncology and BioPharma. Define and drive the scientific agenda for predictive modelling and computational diagnostics by developing advanced multimodal methodologies integrating imaging, molecular diagnostics, omics data, clinical trial datasets, digital biomarkers, and real-world evidence. Champion methodological excellence in multimodal representation learning, computational imaging, omics integration, disease trajectory modelling, and survival prediction. Ensure the scientific rigor, reproducibility, and robustness of AI models used to derive predictive biomarkers, diagnostic intelligence, and patient stratification strategies.
2. Advance Diagnostic Innovation and Computational Disease Stratification
Lead the development of AI-enabled diagnostic frameworks that combine imaging phenotypes, molecular signatures, and clinical data toidentifydisease states earlier and refine biological disease taxonomy. Drive the discovery and validation of multimodal biomarkers that support early diagnosis, disease subtype classification, and treatmentselection. Contribute to the development of companion diagnostics and AI-enabled diagnostic strategies aligned with precision medicine and regulatory requirements, enabling improved patient identification and clinical decision support.
3. Transform Clinical Development Through Predictive Intelligence
Apply multimodal AI methodologies to transform clinical development strategies by improving patient identification, trial enrichment, responder prediction, and endpoint optimisation. Lead advanced reanalysis of clinical trial datasets to uncover responder subgroups,identifypredictive and prognostic biomarkers, and refine patient selection strategies. Use advanced modelling approaches such as causal inference, treatment effect estimation, and dynamic outcome prediction to strengthen development decisions and maximise asset differentiation across the portfolio.
4. Reinforce Foundation ModelswithClinical and Real-World Data
Partner closely with internal AI research teams to translate advances in foundation models into practical biomedical applications. Design reinforcement strategies thatleverageAstraZeneca's clinical trial datasets, real-world healthcare data, and multimodal biological signals to improve model generalisability and predictive power. Develop reusable multimodal representations that capture disease biology across datasets and therapeutic areas, enabling scalable predictive modelling capabilities across the organisation.
5. Integrate Clinical Trials and Real-World EvidenceintoContinuous Learning Systems
Establish predictive modelling frameworks that integrate clinical trial data with real-world evidence to extend insights beyond controlled trial environments. Develop continuous learning systems capable of incorporating longitudinal patient outcomes from electronic health records, claims data, and diagnostic platforms. Enable post-launch monitoring of treatment outcomes and reinforcement of predictive models through real-world evidence, creating feedback loops that strengthen both development and care pathway strategies.
https://jobeax.com/link/VWR6uPzQGmVI7Sk4 Standards for Multimodal AI Validation and Governance
Define and implement enterprise-wide scientific standards for the validation, deployment, and lifecycle management of multimodal AI models. Establish rigorous frameworks for reproducibility, cross-site generalisability, bias mitigation, model explainability, and regulatory-grade evidence generation. Ensure that predictive and diagnostic models meet the scientific, regulatory, and operational requirements necessary for deployment in clinical research and healthcare environments.
Act as a strategic bridge between R&D, diagnostics, and care transformation initiatives by ensuring that multimodal predictive models developed during clinical development translate into scalable tools used in real-world clinical practice. Enable the integration of molecular diagnostics, imaging capabilities, and digital biomarkers into unified predictive frameworks that support patient identification, treatment optimisation, and outcome prediction across the care continuum.
8. Develop Strategic External Partnerships in AI and Diagnostics
Identifyand engage leading academic, AI, diagnostics, and real-world data partners to accelerate innovation in multimodal predictive modelling and computational diagnostics. Evaluate external technologies, datasets, and algorithms to ensure methodological robustness, scalability, and regulatory readiness. Establish collaborative development programs that advance scientific capabilities while protecting intellectual property and ensuring enterprise integration.
9. Drive Cross-Functional Collaboration and Strategic Alignment
Lead multidisciplinary collaboration across research, translational medicine, data science, diagnostics, medical affairs, commercial, and market access teams. Align predictive modelling initiatives with therapeutic area strategies, development priorities, regulatory pathways, and payer evidence requirements. Translate complex methodological insights into clear clinical, regulatory, and strategic implications for senior leadership and global stakeholders.
10. Elevate Organisational Capability in AI-Driven Precision Medicine
Build and institutionalise advanced capabilities in multimodal AI, computational diagnostics, predictive biomarker development, and outcome modelling. Mentor scientific and digital teams to ensure methodological excellence, transparency, and clinical relevance. Contribute to positioning AstraZeneca as a global leader in AI-enabled precision medicine and computational diagnostics.
Contribute to the development of AI for Transform Care team members,providingexpert guidance on precision medicine strategies, companion diagnostics, and AI-embedded clinical decision tools.
Build and sustain strong internal and external collaborations across Commercial, R&D, key markets, academic leaders, and patient communities to ensure prioritised needs are addressed with scientific excellence.